DeYoung M B, Tom C, Dichek D A
Gladstone Institute of Cardiovascular Disease, Department of Medicine, University of California, San Francisco, USA.
Circulation. 2001 Oct 16;104(16):1972-1. doi: 10.1161/hc4101.097110.
Elevated plasma levels of plasminogen activator inhibitor type 1 (PAI-1) are associated with myocardial infarction, atherosclerosis, and restenosis. PAI-1 is increased in atherosclerotic arteries and failed vein grafts. No experimental data, however, support a causal relationship between elevated PAI-1 expression and vascular lesions. Paradoxically, data generated in PAI-1 knockout mice suggest that PAI-1 might decrease lesion formation after arterial injury and that PAI-1 gene transfer might prevent restenosis.
Using the rat carotid balloon injury model and a PAI-1-expressing adenoviral vector, we tested whether elevated arterial PAI-1 expression would alter neointima formation. Compared with control-transduced arteries, neointima formation in PAI-1-transduced arteries was initially retarded. By 14 days, however, the intimas of PAI-1-transduced arteries were significantly larger than intimas of control-transduced arteries (1.6+/-0.1x10(5) versus 1.2+/-0.1x10(5) micrometer(2), n=18 to 19, P<0.03). PAI-1 expression in individual arteries correlated with increased cell proliferation at 4 and 8 days after injury (R=0.6, P<0.02 and P<0.006). PAI-1 expression also correlated with fibrin(ogen) accumulation (R=0.77, P<0.001), and fibrin(ogen) accumulation correlated strongly with proliferation (R=0.86, P<0.00001).
Increased expression of PAI-1 in the artery wall promotes neointima growth after balloon injury. Therefore, despite encouraging data generated in other animal models, PAI-1 is not a promising agent for gene therapy to prevent restenosis. Moreover, our data associate elevated PAI-1 expression with fibrin(ogen) accumulation and increased cell proliferation. These data suggest a mechanism to explain the association between elevated PAI-1 expression and the progression of arterial disease.
纤溶酶原激活物抑制剂1(PAI-1)血浆水平升高与心肌梗死、动脉粥样硬化及再狭窄相关。在动脉粥样硬化动脉及失败的静脉移植物中PAI-1水平升高。然而,尚无实验数据支持PAI-1表达升高与血管病变之间存在因果关系。矛盾的是,PAI-1基因敲除小鼠产生的数据表明,PAI-1可能会减少动脉损伤后的病变形成,且PAI-1基因转移可能预防再狭窄。
利用大鼠颈动脉球囊损伤模型及表达PAI-1的腺病毒载体,我们测试了动脉PAI-1表达升高是否会改变新生内膜形成。与对照转导的动脉相比,PAI-1转导的动脉中新生内膜形成最初受到抑制。然而,到第14天时,PAI-1转导动脉的内膜明显大于对照转导动脉的内膜(1.6±0.1×10⁵对1.2±0.1×10⁵平方微米,n = 18至19,P<0.03)。损伤后4天和8天时,单个动脉中的PAI-1表达与细胞增殖增加相关(R = 0.6,P<0.02和P<0.006)。PAI-1表达也与纤维蛋白(原)积聚相关(R = 0.77,P<0.001),且纤维蛋白(原)积聚与增殖密切相关(R = 0.86,P<0.00001)。
动脉壁中PAI-1表达增加促进球囊损伤后新生内膜生长。因此,尽管在其他动物模型中产生了令人鼓舞的数据,但PAI-1并非预防再狭窄基因治疗的理想药物。此外,我们的数据将PAI-1表达升高与纤维蛋白(原)积聚及细胞增殖增加联系起来。这些数据提示了一种机制来解释PAI-1表达升高与动脉疾病进展之间的关联。